Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.

Orphan drug specialist Amicus Therapeutics is paying Dimerix $30 million cash for U.S. rights to the phase 3 prospect DMX-200 ...

Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) ...

The Melbourne-based company says it has landed one of the biggest licensing deals in Australian biotech history.

Kidney drug developer Dimerix has struck a partnering deal with a Nasdaq listed company that could deliver more than $1 ...

In one of the largest licensing deals in the Australian biotech industry, Dimerix Limited (ASX: DXB) has sealed an exclusive ...

These shares are having a good finish to the week. Let's find out why. The post Why Boss Energy, Capstone, Dimerix, and ...

Amicus pays Dimerix $30M upfront for US rights to DMX-200, a late-stage FSGS therapy, with potential milestone payments of ...

Dimerix (ASX: DXB), an Australian drug developer, has entered into an exclusive US licensing agreement with Amicus ...

Following a meeting with the US FDA, clinical-stage biotech Dimerix has confirmed the appropriate primary endpoint for full ...

Island Pharmaeuticals, Dimerix and Tryptamine Therapeutics are among ASX health stocks reporting quarterly results this week.

NZ based wounds management house Aroa Biosurgery says the US tariff imposed on its products should be less than the general 10% Kiwi impost.